文献速递类风湿关节炎

羟氯喹单用及联用阿奇霉素治疗类风湿关节炎的风险:多国回顾性研究

Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study.
PubMed 文献 · Lancet Rheumatol · 2020-08-21

该多国回顾性研究比较类风湿关节炎患者启用羟氯喹与启用柳氮磺吡啶的30天严重不良事件风险,并分析羟氯喹联用阿奇霉素的风险。短期羟氯喹单用未见严重不良事件风险增加,但长期使用与心血管死亡风险升高相关;联用阿奇霉素短期即增加心血管死亡、胸痛或心绞痛及心力衰竭风险。

要点

  • 短期羟氯喹单用与柳氮磺吡啶相比,30天严重不良事件风险无增加。
  • 羟氯喹联用阿奇霉素短期增加心血管死亡和心力衰竭风险。

核心结论

  • 羟氯喹短期治疗类风湿关节炎未见严重不良事件风险增加,但长期使用与心血管死亡风险升高相关。
  • 联用阿奇霉素即使在短期也增加心力衰竭和心血管死亡风险,需权衡获益与风险。

研究设计与样本

  • 多国回顾性研究,采用新用户队列比较羟氯喹与柳氮磺吡啶,随访30天,研究16种严重不良事件。
  • 采用自身对照病例系列在更广泛人群中进一步验证安全性。
  • 数据来自德国、日本、荷兰、西班牙、英国和美国的14个索赔数据或电子病历来源。
  • 使用倾向评分分层和阴性对照结局校准控制混杂,拟合Cox模型估计校准HR。

主要发现

  • 纳入羟氯喹使用者956 374例,柳氮磺吡啶使用者310 350例,羟氯喹联合阿奇霉素使用者323 122例,羟氯喹联合阿莫西林使用者351 956例。
  • 30天羟氯喹与柳氮磺吡啶比较未发现严重不良事件风险增加,自身对照病例系列证实该结果。

临床怎么用

  • 对类风湿关节炎患者短期使用羟氯喹时,严重不良事件风险未见增加。
  • 长期使用羟氯喹需关注心血管死亡风险,应个体化评估获益与风险。
  • 羟氯喹联用阿奇霉素时需警惕短期心血管死亡和心力衰竭风险,谨慎考虑联用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hydroxychloroquine, a drug commonly used in the treatment of rheumatoid arthritis, has received much negative publicity for adverse events associated with its authorisation for emergency use to treat patients with COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin, to determine the risk associated with its use in routine care in patients with rheumatoid arthritis. METHODS: In this multinational, retrospective study, new user cohort studies in patients with rheumatoid arthritis aged 18 years or older and initiating hydroxychloroquine were compared with those initiating sulfasalazine and followed up over 30 days, with 16 severe adverse events studied. Self-controlled case series were done to further establish safety in wider populations, and included all users of hydroxychloroquine regardless of rheumatoid arthritis status or indication. Separately, severe adverse events associated with hydroxychloroquine plus azithromycin (compared with hydroxychloroquine plus amoxicillin) were studied. Data comprised 14 sources of claims data or electronic medical records from Germany, Japan, the Netherlands, Spain, the UK, and the USA. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate calibrated hazard ratios (HRs) according to drug use. Estimates were pooled where the I 2 value was less than 0·4. FINDINGS: The study included 956 374 users of hydroxychloroquine, 310 350 users of sulfasalazine, 323 122 users of hydroxychloroquine plus azithromycin, and 351 956 users of hydroxychloroquine plus amoxicillin. No excess risk of severe adverse events was identified when 30-day hydroxychloroquine and sulfasalazine use were compared. Self-controlled case series confirmed these findings. However, long-term use of hydroxychloroquine appeared to be associated with increased cardiovascular mortality (calibrated HR 1·65 [95% CI 1·12-2·44]). Addition of azithromycin appeared to be associated with an increased risk of 30-day cardiovascular mortality (calibrated HR 2·19 [95% CI 1·22-3·95]), chest pain or angina (1·15 [1·05-1·26]), and heart failure (1·22 [1·02-1·45]). INTERPRETATION: Hydroxychloroquine treatment appears to have no increased risk in the short term among patients with rheumatoid arthritis, but in the long term it appears to be associated with excess cardiovascular mortality. The addition of azithromycin increases the risk of heart failure and cardiovascular mortality even in the short term. We call for careful consideration of the benefit-risk trade-off when counselling those on hydroxychloroquine treatment. FUNDING: National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, NIHR Senior Research Fellowship programme, US National Institutes of Health, US Department of Veterans Affairs, Janssen Research and Development, IQVIA, Korea Health Industry Development Institute through the Ministry of Health and Welfare Republic of Korea, Versus Arthritis, UK Medical Research Council Doctoral Training Partnership, Foundation Alfonso Martin Escudero, Innovation Fund Denmark, Novo Nordisk Foundation, Singapore Ministry of Health's National Medical Research Council Open Fund Large Collaborative Grant, VINCI, Innovative Medicines Initiative 2 Joint Undertaking, EU's Horizon 2020 research and innovation programme, and European Federation of Pharmaceutical Industries and Associations.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Lane JCE, Weaver J, Kostka K, et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. 2020. PMID: 32864627. doi:10.1016/S2665-9913(20)30276-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。